ATE406915T1 - Mittel zur regulierung der sekretion von pankreassaft mit einem lpa-rezeptor-regler - Google Patents
Mittel zur regulierung der sekretion von pankreassaft mit einem lpa-rezeptor-reglerInfo
- Publication number
- ATE406915T1 ATE406915T1 AT02746091T AT02746091T ATE406915T1 AT E406915 T1 ATE406915 T1 AT E406915T1 AT 02746091 T AT02746091 T AT 02746091T AT 02746091 T AT02746091 T AT 02746091T AT E406915 T1 ATE406915 T1 AT E406915T1
- Authority
- AT
- Austria
- Prior art keywords
- pancreatic juice
- secretion
- regulating
- agent
- lpa receptor
- Prior art date
Links
- 210000001819 pancreatic juice Anatomy 0.000 title abstract 4
- 230000028327 secretion Effects 0.000 title abstract 3
- 108091006073 receptor regulators Proteins 0.000 title 1
- 230000001105 regulatory effect Effects 0.000 title 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 abstract 3
- 102000004137 Lysophosphatidic Acid Receptors Human genes 0.000 abstract 1
- 108090000642 Lysophosphatidic Acid Receptors Proteins 0.000 abstract 1
- 241000700157 Rattus norvegicus Species 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 230000001539 anorectic effect Effects 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000001802 infusion Methods 0.000 abstract 1
- 239000008141 laxative Substances 0.000 abstract 1
- 230000002475 laxative effect Effects 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 210000003462 vein Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Non-Alcoholic Beverages (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001216133 | 2001-07-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE406915T1 true ATE406915T1 (de) | 2008-09-15 |
Family
ID=19050646
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02746091T ATE406915T1 (de) | 2001-07-17 | 2002-07-16 | Mittel zur regulierung der sekretion von pankreassaft mit einem lpa-rezeptor-regler |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20040171582A1 (de) |
| EP (1) | EP1415667B1 (de) |
| JP (1) | JPWO2003007991A1 (de) |
| AT (1) | ATE406915T1 (de) |
| DE (1) | DE60228732D1 (de) |
| ES (1) | ES2312588T3 (de) |
| WO (1) | WO2003007991A1 (de) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050113283A1 (en) * | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
| WO2004002530A1 (ja) * | 2002-06-26 | 2004-01-08 | Ono Pharmaceutical Co., Ltd. | 慢性疾患治療剤 |
| TW200408393A (en) | 2002-10-03 | 2004-06-01 | Ono Pharmaceutical Co | Antagonist of lysophosphatidine acid receptor |
| WO2005012269A1 (ja) | 2003-08-05 | 2005-02-10 | Ajinomoto Co., Inc. | 新規アゾール化合物 |
| JP4779650B2 (ja) * | 2003-12-26 | 2011-09-28 | 小野薬品工業株式会社 | 高活性型リゾホスファチジン酸およびそれを用いたスクリーニング方法 |
| JPWO2006103750A1 (ja) * | 2005-03-29 | 2008-09-04 | 日本ハム株式会社 | 肥満改善用組成物、機能性食品及び医薬用組成物 |
| WO2009082491A1 (en) * | 2007-12-26 | 2009-07-02 | Alp Life Sciences, Llc | Nanovesontm: treatment, biomarkers and diagnostic tests for liver diseases and comorbid diseases |
| WO2010016590A1 (ja) | 2008-08-07 | 2010-02-11 | 国立大学法人 長崎大学 | 全身性疼痛症候群の治療または予防薬 |
| WO2010068775A2 (en) | 2008-12-11 | 2010-06-17 | Amira Pharmaceuticals, Inc. | Alkyne antagonists of lysophosphatidic acid receptors |
| GB2466121B (en) * | 2008-12-15 | 2010-12-08 | Amira Pharmaceuticals Inc | Antagonists of lysophosphatidic acid receptors |
| GB2470833B (en) * | 2009-06-03 | 2011-06-01 | Amira Pharmaceuticals Inc | Polycyclic antagonists of lysophosphatidic acid receptors |
| IN2012DN00754A (de) | 2009-08-04 | 2015-06-19 | Amira Pharmaceuticals Inc | |
| GB2474748B (en) | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| GB2474120B (en) * | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
| CN103596947A (zh) | 2011-04-05 | 2014-02-19 | 艾米拉医药股份有限公司 | 用于治疗纤维化、疼痛、癌症和呼吸、过敏性、神经系统疾病或心血管疾病的基于3-或5-联苯-4-基异噁唑的化合物 |
| AU2012296662A1 (en) | 2011-08-15 | 2014-03-27 | Intermune, Inc. | Lysophosphatidic acid receptor antagonists |
| AU2015242791B2 (en) * | 2014-04-04 | 2017-08-17 | Osaka University | Drug Delivery Enhancer Comprising Substance For Activating Lysophospholipid Receptors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1865499A (en) * | 1997-12-30 | 1999-07-26 | Allelix Biopharmaceuticals Inc. | Identification of lysolipid receptors involved in inflammatory response |
| US6380177B1 (en) * | 1999-06-25 | 2002-04-30 | Atairgin Technologies, Inc. | LPA analogs as agonists of the Edg2 LPA receptor |
| ATE420878T1 (de) * | 2000-02-18 | 2009-01-15 | Kyowa Hakko Kirin Co Ltd | Isoxazol- und thiazolverbindungen und ihre verwendung als medikamente |
| CA2402038C (en) * | 2000-03-17 | 2011-03-15 | The University Of Tennessee Research Corporation | Lpa receptor agonists and antagonists and methods of use |
| DE60234318D1 (de) * | 2001-02-08 | 2009-12-24 | Ono Pharmaceutical Co | Mittel zur behandlung von harnwegserkrankungen, umfassend mittel zur kontrolle des lpa-rezeptors |
-
2002
- 2002-07-16 AT AT02746091T patent/ATE406915T1/de not_active IP Right Cessation
- 2002-07-16 WO PCT/JP2002/007213 patent/WO2003007991A1/ja not_active Ceased
- 2002-07-16 DE DE60228732T patent/DE60228732D1/de not_active Expired - Fee Related
- 2002-07-16 EP EP02746091A patent/EP1415667B1/de not_active Expired - Lifetime
- 2002-07-16 ES ES02746091T patent/ES2312588T3/es not_active Expired - Lifetime
- 2002-07-16 US US10/483,815 patent/US20040171582A1/en not_active Abandoned
- 2002-07-16 JP JP2003513596A patent/JPWO2003007991A1/ja not_active Withdrawn
-
2008
- 2008-04-30 US US12/112,538 patent/US20080234230A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003007991A1 (en) | 2003-01-30 |
| US20080234230A1 (en) | 2008-09-25 |
| EP1415667A1 (de) | 2004-05-06 |
| ES2312588T3 (es) | 2009-03-01 |
| US20040171582A1 (en) | 2004-09-02 |
| EP1415667A4 (de) | 2006-04-19 |
| DE60228732D1 (de) | 2008-10-16 |
| EP1415667B1 (de) | 2008-09-03 |
| JPWO2003007991A1 (ja) | 2004-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE406915T1 (de) | Mittel zur regulierung der sekretion von pankreassaft mit einem lpa-rezeptor-regler | |
| DE60321318D1 (de) | Gewinnung von delta-9 tetrahydrocannabinol | |
| PE97599A1 (es) | Sal tartrato de un dipeptido sustituido | |
| DK1104294T3 (da) | Sammensatninger og Fremgangsmåder til behandling af unormal celleproliferation | |
| PL285591A1 (en) | Method for manufacturing new imidazolilalkenecrbxylic acids | |
| AU640417B2 (en) | Substituted 5-((tetrazolyl)alkenyl)imidazoles | |
| TW200618509A (en) | System, apparatus, computer program product and method for controlling terminal output power | |
| BR9712637A (pt) | Método e equipamento para efetuar um movimento rápido para baixo em um sistema de controle de potência da ligação enviada de um telefone celular | |
| BR9906796A (pt) | Método para a administração de análogos de insulina monoméricos | |
| EP0437103A3 (de) | Substituierte 5-(Alkyl)-carboxamid-Imidazole | |
| DE69401011D1 (de) | Carbocyclische Sulfonamide als Agoniste oder Antagoniste von PGEZ | |
| EE05402B1 (et) | Meetod bensimidasooli-tüüpi ühendite valmistamiseks ning k?rvalsaadusena moodustunud sulfoonide eemaldamiseks | |
| UA49880C2 (uk) | Дигідрат ерпоcартану, фармацевтична композиція, спосіб отримання твердої дозованої форми, спосіб блокування рецепторів ангіотензину іі | |
| NO934098L (no) | Galaninantagonist | |
| HUT56077A (en) | Process for producing n-(imidazolyl-alkyl)-alanyl derivatives with substituents and pharmaceutical compositions containing them as active components | |
| WO2006074226A3 (en) | Prevention of thrombotic disorders with active vitamin d compounds or mimics thereof | |
| MY129355A (en) | Substituted carbostyril derivatives as 5-ht1a receptor subtype agonists | |
| WO2004041208A3 (en) | Controlled absorption of mixed thyroyd hormone formulations | |
| DE50304970D1 (de) | Progesteronrezeptormodulatoren mit erhöhter antigonadotroper aktivität für die weibliche fertilitätskontrolle und hormonersatztherapie | |
| Gallant et al. | The in vivo effect of indomethacin and prostaglandin E2 on ACTH and DBCAMP-induced steroidogenesis in hypophysectomized rats | |
| WO2005051401A3 (en) | Prevention and treatment of hypertensive heart diseases by the selective estrogens 8beta-vinyl-estra-1,3,5(10)-trien-3,17beta-diol and 17beta-fluor-9alpha-vinyl-estra-1,3,5(10)-trien-3,16alpha-diol | |
| PL374481A1 (en) | Remedy for diabetes | |
| Jovanovic et al. | Analysis of factors influencing chronic renal failure progression | |
| Llontop et al. | The methyl-CpG-binding protein 2 (Mecp2) regulates the hypothalamic mitochondrial function and white adipose tissue lipid metabolism | |
| SE9404192D0 (sv) | New process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |